Pediatric ALL Drug Response Profiles from 25 Patient Samples

Containing ex vivo drug screening results for 25 pediatric acute lymphoblastic leukemia (ALL) patient samples tested against a panel of 50 clinically relevant and experimental agents. It was generated using the ELDA platform, which employs time-lapse microscopy and image analysis to quantify real-time treatment response. The author is Samara Sousa Mariano.

Use Cases

• Analyze drug sensitivity and resistance patterns across the 50-agent panel for each of the 25 patient samples.
• Investigate correlations in activity profiles for drugs with similar mechanisms of action as identified by the ELDA assay.
• Compare ex vivo drug response data, such as for dexamethasone and vincristine, with in vivo validation results.

Strengths

• Data is derived from 25 primary pediatric ALL patient samples, providing patient-specific biological context.
• Drug panel includes 50 clinically relevant and experimental agents for broad therapeutic coverage.
• Methodology validated against established cytotoxicity assays (MTT, Calcein-AM) and supported by in vivo validation.

Limitations

• The dataset is small in file size (29.8 KB), indicating limited scope and likely a summary or aggregated view rather than raw high-throughput data.
• Sample size is limited to 25 pediatric ALL cases, which may not capture the full heterogeneity of the disease.
• Specific column structure, row count, and granular sample-level data are unknown from the provided description.

Provenance

Source

figshare, author Samara Sousa Mariano.

Collection Method

Generated via the ELDA (Ex vivo Leukemia Drug Advisor) platform using time-lapse bright-field microscopy and custom image analysis on primary ALL cells co-cultured in a 3D collagen matrix.

Freshness

Last updated 2026-03-20.